Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL)

Dawn L. Hershman, Lawrence H. Kushi, Grace Clarke Hillyer, Ellie Coromilas, Donna Buono, Lois Lamerato, Dana H. Bovbjerg, Jeanne S. Mandelblatt, Wei Yann Tsai, Xiaobo Zhong, Judith S. Jacobson, Jason D. Wright, Alfred I. Neugut

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Non-adherence to adjuvant endocrine therapy (ET) for breast cancer (BC) is common. Our goal was to determine the associations between psychosocial factors and ET non-persistence. We recruited women with BC receiving care in an integrated healthcare system between 2006 and 2010. Using a subset of patients treated with ET, we investigated factors related to ET non-persistence (discontinuation) based on pharmacy records (≥90 days gap). Serial interviews were conducted at baseline and every 6 months. The Functional Assessment of Cancer Therapy (FACT), Medical Outcomes Survey, Treatment Satisfaction Questionnaire (TSQM), Impact of Events Scale (IES), Interpersonal Processes of Care measure, and Decision-making beliefs and concerns were measured. Multivariate models assessed factors associated with non-persistence. Of the 523 women in our final cohort who initiated ET and had a subsequent evaluation, 94 (18 %) were non-persistent over a 2-year follow-up. The cohort was primarily white (74.4 %), stage 1 (60.6 %), and on an aromatase inhibitor (68.1 %). Women in the highest income category had a lower odds of being non-persistent (OR 0.43, 95 % CI 0.23–0.81). Quality of life and attitudes toward ET at baseline were associated with non-persistence. At follow-up, the FACT, TSQM, and IES were associated with non-persistence (p < 0.001). Most women continued ET. Women who reported a better attitude toward ET, better quality of life, and more treatment satisfaction, were less likely to be non-persistent and those who reported intrusive/avoidant thoughts were more likely to be non-persistent. Interventions to enhance the psychosocial well-being of patients should be evaluated to increase adherence.

Original languageEnglish (US)
Pages (from-to)133-143
Number of pages11
JournalBreast Cancer Research and Treatment
Volume157
Issue number1
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Quality of Health Care
Breast Neoplasms
Psychology
Therapeutics
Quality of Life
Aromatase Inhibitors
Process Assessment (Health Care)
Neoplasms
Decision Making
Interviews
Delivery of Health Care

Keywords

  • Adherence
  • Breast cancer
  • Psychosocial factors
  • Quality of life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer : the Breast Cancer Quality of Care Study (BQUAL). / Hershman, Dawn L.; Kushi, Lawrence H.; Hillyer, Grace Clarke; Coromilas, Ellie; Buono, Donna; Lamerato, Lois; Bovbjerg, Dana H.; Mandelblatt, Jeanne S.; Tsai, Wei Yann; Zhong, Xiaobo; Jacobson, Judith S.; Wright, Jason D.; Neugut, Alfred I.

In: Breast Cancer Research and Treatment, Vol. 157, No. 1, 01.05.2016, p. 133-143.

Research output: Contribution to journalArticle

Hershman, DL, Kushi, LH, Hillyer, GC, Coromilas, E, Buono, D, Lamerato, L, Bovbjerg, DH, Mandelblatt, JS, Tsai, WY, Zhong, X, Jacobson, JS, Wright, JD & Neugut, AI 2016, 'Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL)', Breast Cancer Research and Treatment, vol. 157, no. 1, pp. 133-143. https://doi.org/10.1007/s10549-016-3788-x
Hershman, Dawn L. ; Kushi, Lawrence H. ; Hillyer, Grace Clarke ; Coromilas, Ellie ; Buono, Donna ; Lamerato, Lois ; Bovbjerg, Dana H. ; Mandelblatt, Jeanne S. ; Tsai, Wei Yann ; Zhong, Xiaobo ; Jacobson, Judith S. ; Wright, Jason D. ; Neugut, Alfred I. / Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer : the Breast Cancer Quality of Care Study (BQUAL). In: Breast Cancer Research and Treatment. 2016 ; Vol. 157, No. 1. pp. 133-143.
@article{7f3e99fdbe12419f92afc6f7e04ffad3,
title = "Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL)",
abstract = "Non-adherence to adjuvant endocrine therapy (ET) for breast cancer (BC) is common. Our goal was to determine the associations between psychosocial factors and ET non-persistence. We recruited women with BC receiving care in an integrated healthcare system between 2006 and 2010. Using a subset of patients treated with ET, we investigated factors related to ET non-persistence (discontinuation) based on pharmacy records (≥90 days gap). Serial interviews were conducted at baseline and every 6 months. The Functional Assessment of Cancer Therapy (FACT), Medical Outcomes Survey, Treatment Satisfaction Questionnaire (TSQM), Impact of Events Scale (IES), Interpersonal Processes of Care measure, and Decision-making beliefs and concerns were measured. Multivariate models assessed factors associated with non-persistence. Of the 523 women in our final cohort who initiated ET and had a subsequent evaluation, 94 (18 {\%}) were non-persistent over a 2-year follow-up. The cohort was primarily white (74.4 {\%}), stage 1 (60.6 {\%}), and on an aromatase inhibitor (68.1 {\%}). Women in the highest income category had a lower odds of being non-persistent (OR 0.43, 95 {\%} CI 0.23–0.81). Quality of life and attitudes toward ET at baseline were associated with non-persistence. At follow-up, the FACT, TSQM, and IES were associated with non-persistence (p < 0.001). Most women continued ET. Women who reported a better attitude toward ET, better quality of life, and more treatment satisfaction, were less likely to be non-persistent and those who reported intrusive/avoidant thoughts were more likely to be non-persistent. Interventions to enhance the psychosocial well-being of patients should be evaluated to increase adherence.",
keywords = "Adherence, Breast cancer, Psychosocial factors, Quality of life",
author = "Hershman, {Dawn L.} and Kushi, {Lawrence H.} and Hillyer, {Grace Clarke} and Ellie Coromilas and Donna Buono and Lois Lamerato and Bovbjerg, {Dana H.} and Mandelblatt, {Jeanne S.} and Tsai, {Wei Yann} and Xiaobo Zhong and Jacobson, {Judith S.} and Wright, {Jason D.} and Neugut, {Alfred I.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1007/s10549-016-3788-x",
language = "English (US)",
volume = "157",
pages = "133--143",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer

T2 - the Breast Cancer Quality of Care Study (BQUAL)

AU - Hershman, Dawn L.

AU - Kushi, Lawrence H.

AU - Hillyer, Grace Clarke

AU - Coromilas, Ellie

AU - Buono, Donna

AU - Lamerato, Lois

AU - Bovbjerg, Dana H.

AU - Mandelblatt, Jeanne S.

AU - Tsai, Wei Yann

AU - Zhong, Xiaobo

AU - Jacobson, Judith S.

AU - Wright, Jason D.

AU - Neugut, Alfred I.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Non-adherence to adjuvant endocrine therapy (ET) for breast cancer (BC) is common. Our goal was to determine the associations between psychosocial factors and ET non-persistence. We recruited women with BC receiving care in an integrated healthcare system between 2006 and 2010. Using a subset of patients treated with ET, we investigated factors related to ET non-persistence (discontinuation) based on pharmacy records (≥90 days gap). Serial interviews were conducted at baseline and every 6 months. The Functional Assessment of Cancer Therapy (FACT), Medical Outcomes Survey, Treatment Satisfaction Questionnaire (TSQM), Impact of Events Scale (IES), Interpersonal Processes of Care measure, and Decision-making beliefs and concerns were measured. Multivariate models assessed factors associated with non-persistence. Of the 523 women in our final cohort who initiated ET and had a subsequent evaluation, 94 (18 %) were non-persistent over a 2-year follow-up. The cohort was primarily white (74.4 %), stage 1 (60.6 %), and on an aromatase inhibitor (68.1 %). Women in the highest income category had a lower odds of being non-persistent (OR 0.43, 95 % CI 0.23–0.81). Quality of life and attitudes toward ET at baseline were associated with non-persistence. At follow-up, the FACT, TSQM, and IES were associated with non-persistence (p < 0.001). Most women continued ET. Women who reported a better attitude toward ET, better quality of life, and more treatment satisfaction, were less likely to be non-persistent and those who reported intrusive/avoidant thoughts were more likely to be non-persistent. Interventions to enhance the psychosocial well-being of patients should be evaluated to increase adherence.

AB - Non-adherence to adjuvant endocrine therapy (ET) for breast cancer (BC) is common. Our goal was to determine the associations between psychosocial factors and ET non-persistence. We recruited women with BC receiving care in an integrated healthcare system between 2006 and 2010. Using a subset of patients treated with ET, we investigated factors related to ET non-persistence (discontinuation) based on pharmacy records (≥90 days gap). Serial interviews were conducted at baseline and every 6 months. The Functional Assessment of Cancer Therapy (FACT), Medical Outcomes Survey, Treatment Satisfaction Questionnaire (TSQM), Impact of Events Scale (IES), Interpersonal Processes of Care measure, and Decision-making beliefs and concerns were measured. Multivariate models assessed factors associated with non-persistence. Of the 523 women in our final cohort who initiated ET and had a subsequent evaluation, 94 (18 %) were non-persistent over a 2-year follow-up. The cohort was primarily white (74.4 %), stage 1 (60.6 %), and on an aromatase inhibitor (68.1 %). Women in the highest income category had a lower odds of being non-persistent (OR 0.43, 95 % CI 0.23–0.81). Quality of life and attitudes toward ET at baseline were associated with non-persistence. At follow-up, the FACT, TSQM, and IES were associated with non-persistence (p < 0.001). Most women continued ET. Women who reported a better attitude toward ET, better quality of life, and more treatment satisfaction, were less likely to be non-persistent and those who reported intrusive/avoidant thoughts were more likely to be non-persistent. Interventions to enhance the psychosocial well-being of patients should be evaluated to increase adherence.

KW - Adherence

KW - Breast cancer

KW - Psychosocial factors

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84963773390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963773390&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3788-x

DO - 10.1007/s10549-016-3788-x

M3 - Article

C2 - 27086286

AN - SCOPUS:84963773390

VL - 157

SP - 133

EP - 143

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -